The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019: what changed
24 changes of wording, as read on 20 Nov 2026.
24
- amended
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 3 · Amendment of regulation 2 (interpretation)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 4 · Insertion of regulation 2A (list of countries for the purpose of the definition of “marketing authorization”)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 5 · Amendment of regulation 3 (sponsor of a clinical trial)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 6 · Omission of regulation 4 (responsibility for functions under the Directive)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 7 · Amendment of regulation 13 (supply of investigational medicinal products for the purpose of clinical trials)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 8 · Amendment of regulation 15 (ethics committee opinion)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 10 · Amendment of regulation 21 (clinical trials conducted in third countries)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 11 · Insertion of regulation 27B (publication of information)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 13 · Amendment of regulation 31A (trial master file and archiving)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 15 · Amendment of regulation 34 (clinical trials conducted in third countries)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 16 · Amendment of regulation 35 (annual list of suspected serious adverse reactions and safety report)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 17 · Amendment of regulation 36 (requirement for authorisation to manufacture or import investigational medicinal products)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 18 · Amendment of regulation 43 (qualified persons)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 19 · Insertion of regulation 43A (approved country for import)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 20 · Amendment of regulation 45 (suspension and revocation of manufacturing authorisation)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 21 · Amendment of regulation 48 (infringement notices)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 22 · Amendment of regulation 56 (transitional provisions)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 23 · Insertion of regulation 57 (functions in relation to good clinical practice)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 24 · Amendment of Schedule 3 (particulars and documents that must accompany an application for an ethics committee opinion, a request for authorisation, a notice of amendment and a notification of the conclusion of a trial)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 25 · Amendment of Schedule 7 (standard provisions for manufacturing authorisations)
- amended
Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, 26 · Insertion of Schedule 13 (transitional provisions in relation to EU Exit)
- amended
- amended